Compare Novavax Inc (NVAX) vs Shell PLC (SHEL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Shell PLC — how do they compare? Novavax Inc trades at $8.08 (market cap $1.30B), while Shell PLC trades at $87.12 (market cap $235.24B). The key difference: Shell PLC is far larger — about 181× Novavax Inc's market cap, and Shell PLC pays a 3.63% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| NVAX | SHEL | |
|---|---|---|
Market Cap | $1.30B | $235.24B |
Sector | Health | Energy |
52-Week High | $11.19 | $94.15 |
52-Week Low | $6.22 | $70.31 |
Enterprise Value | $800.50M | $287.77B |
Dividend Yield | — | 3.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $8.08, down 1.64% on the day, with a bearish technical signal but strong recent earnings beats. The company reported $1.12B revenue in 2025 with a net income of $440.30M, though 2026 projections show a return to losses. Analyst consensus is bullish with a $14.00 price target, but negative shareholder equity and cash flow concerns persist.
Outlook remains mixed: strong valuation ratios and analyst support suggest upside potential, but negative cash flows, high liabilities, and projected 2026 losses pose significant risks. Investor sentiment is cautious amid recent stock declines and shareholder dissent highlighted in recent news.
Shell (SHEL) trades at $87.20, showing modest daily decline but maintaining strong technical momentum with bullish moving averages. The stock offers attractive valuation with P/E of 13.43 and P/S of 0.94, supported by solid profitability metrics including 7.01% net margin and 10.64% ROE. Recent Q1 2026 earnings beat expectations at $2.44 EPS versus $2.14 forecast, while the company expands LNG operations in the Caribbean and advances Venezuela gas projects.
Shell presents compelling value with 30% upside to consensus price target of $114.13, supported by 69% analyst buy ratings. However, investors face risks from volatile oil prices, Middle East production disruptions, and declining cash flow trends. The current technical overbought condition suggests potential near-term consolidation before further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Shell PLC
Shell is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.7 million barrels of liquids and 8.7 billion cubic feet of natural gas per day. At year-end 2021, reserves stood at 9.2 billion barrels of oil equivalent, 50% of which consisted of liquids. Its production and reserves are in Europe, Asia, Oceania, Africa, and North and South America. The company operates refineries with capacity of 1.8 mmb/d located in the Americas, Asia, Africa, and Europe and sells 15 mtpa of chemicals. Its largest chemical plants, often integrated with its local refineries, are in Central Europe, China, Singapore, and North America.
Read more on SHEL →
